<DOC>
	<DOCNO>NCT00518284</DOCNO>
	<brief_summary>The purpose study investigate prevention Restenosis follow Revascularization superficial Femoral Artery ( SFA )</brief_summary>
	<brief_title>Prevention Restenosis Following Revascularization</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male nonpregnant nonlactating female great equal 18 year age . All female child bear potential must negative serum pregnancy test Patient determine peripheral artery disease ( PAD ) classify Rutherford category 14 ( grade I/II ) mild , moderate , severe claudication ischemic rest pain Patient de novo lesion cause occlusion angiographic stenosis least 50 % superficial femoral artery Patient single multiple lesion locate superficial femoral artery total length 515 cm . Normal vessel diameter SFA 46 mm Patient must visibly patent ( angiography ) popliteal artery target lesion No residual flow limit dissection residual stenosis great 30 % ( visual estimate ) percutaneous balloon angioplasty ( PTA ) provisional stenting . Treatment provisional stenting allow flowlimiting dissection , grade C/D great 30 % residual stenosis angiographically angioplasty alone . No target vessel thrombosis confirm angiography postPTA procedure No distal embolization within target limb Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent Form prior premedication , prior performance revascularization procedure , prior participation studyrelated activity Women child bear potential use adequate contraception Patients experience acute onset claudication History bleeding diathesis , coagulopathy , platelet disorder , thrombocytopenia Patients lesion require treatment atherectomy primary stenting Target lesion PTA failure would require treatment provisional stenting 2 stent Patient life expectancy le 36 month factor make clinical follow difficult ( fixed address , etc ) Additional plan vascular procedure treat extremity ( note concurrent endovascular treatment iliac disease allowable ) Patient immunosuppressed HIV positive Any individual may refuse blood transfusion Documented major gastrointestinal bleeding within 3 month The following lab value baseline exclusionary : Serum creatinine great equal 2.5 mg/dl Platelet count le 100,000 cells/mm^3 Uncorrectable coagulopathy international normalize ratio ( INR ) great 2.0 Absolute Neutrophil Count ( ANC ) less 2000 cell mm^3 Hemoglobin ( Hgb ) less 9 g/dl Total Bilirubin great 1.5 mg/dl Alanine transaminase ( SGPT ) great 2.5 x upper limit normal range ( ULN ) Aspartate transaminase ( SGOT ) great 2.5 x ULN Alkaline phosphatase great 2.5 x ULN Total cholesterol great 350 mg/dl Low Density Lipoprotein great 200 mg/dl Known allergies/hypersensitivity/contraindication study drug , taxanes , require study treatment : aspirin , heparin , clopidogrel bisulfate , stent material , ticlopidine , dipyridamole Patient treat bivalirudin ( Angiomax ) Preexisting sensory neuropathy National Cancer Institute ( NCI ) Toxicity Grade &gt; 1 Previous participation another study investigational drug device within past 30 day current enrollment clinical protocol investigational trial Renal failure require hemodialysis Lower extremity pedal pulse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Restenosis</keyword>
	<keyword>Superficial Femoral Artery</keyword>
	<keyword>Prevention restenosis</keyword>
	<keyword>Revascularization superficial Femoral Artery</keyword>
</DOC>